Insider Stock Trading History of Champsi Farah


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Champsi Farah since year 2005. The trader's CIK number is 1198321. At the time of this reporting, Champsi Farah is the Director of Kite Pharma, Inc. . (stock ticker symbol KITE). See this page for all insider trading activities at Kite Pharma, Inc. .

Note that in the past CHAMPSI FARAH also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Champsi Farah since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-06-14 KITE Kite Pharma, Inc. Sale 15,000 90.40 1,356,000
2017-06-16 KITE Kite Pharma, Inc. Sale 5,450 88.11 480,199
2017-04-27 KITE Kite Pharma, Inc. Sale 16,551 82.77 1,369,926
2017-04-28 KITE Kite Pharma, Inc. Sale 2,617 82.59 216,138
2017-04-26 KITE Kite Pharma, Inc. Sale 51,312 82.89 4,253,251
2017-04-24 KITE Kite Pharma, Inc. Sale 25,818 82.34 2,125,854
2017-04-25 KITE Kite Pharma, Inc. Sale 46,783 82.92 3,879,480
2017-04-17 KITE Kite Pharma, Inc. Sale 43,101 82.77 3,567,469
2017-04-13 KITE Kite Pharma, Inc. Sale 72,275 82.39 5,954,737
2015-06-30 KITE Kite Pharma, Inc. Sale 664,102 62.55 41,538,251
2014-07-29 IMDZ Immune Design Corp. Buy 299,559 12.00 3,594,708
2014-06-23 ZSPH Zs Pharma, Inc. Buy 200,000 18.00 3,600,000
2014-05-07 SCYX Scynexis Inc Buy 900,000 10.00 9,000,000
2013-10-23 CMRX Chimerix Inc Sale 447,499 15.51 6,940,709
2010-06-30 SNSS Sunesis Pharmaceuticals Inc Buy 11,912,224 .28 3,275,861
2009-12-14 SNSS Sunesis Pharmaceuticals Inc Sale 2,232,464 2.01 4,485,020
2009-10-16 CORT Corcept Therapeutics Inc Buy 349,651 1.38 482,518

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Champsi Farah (Director of Kite Pharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.